000128894 001__ 128894
000128894 005__ 20240228143355.0
000128894 0247_ $$2doi$$a10.1158/1078-0432.CCR-16-0702
000128894 0247_ $$2pmid$$apmid:27803067
000128894 0247_ $$2pmc$$apmc:PMC5503450
000128894 0247_ $$2ISSN$$a1078-0432
000128894 0247_ $$2ISSN$$a1557-3265
000128894 0247_ $$2altmetric$$aaltmetric:12537085
000128894 037__ $$aDKFZ-2017-04907
000128894 041__ $$aeng
000128894 082__ $$a610
000128894 1001_ $$0P:(DE-He78)3da06896bf2a50a84d40c33c3b7a9b3e$$aKickingereder, Philipp$$b0$$eFirst author$$udkfz
000128894 245__ $$aLarge-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response.
000128894 260__ $$aPhiladelphia, Pa. [u.a.]$$bAACR$$c2016
000128894 3367_ $$2DRIVER$$aarticle
000128894 3367_ $$2DataCite$$aOutput Types/Journal article
000128894 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524748826_17079
000128894 3367_ $$2BibTeX$$aARTICLE
000128894 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128894 3367_ $$00$$2EndNote$$aJournal Article
000128894 520__ $$aAntiangiogenic treatment with bevacizumab, a mAb to the VEGF, is the single most widely used therapeutic agent for patients with recurrent glioblastoma. A major challenge is that there are currently no validated biomarkers that can predict treatment outcome. Here we analyze the potential of radiomics, an emerging field of research that aims to utilize the full potential of medical imaging.A total of 4,842 quantitative MRI features were automatically extracted and analyzed from the multiparametric tumor of 172 patients (allocated to a discovery and validation set with a 2:1 ratio) with recurrent glioblastoma prior to bevacizumab treatment. Leveraging a high-throughput approach, radiomic features of patients in the discovery set were subjected to a supervised principal component (superpc) analysis to generate a prediction model for stratifying treatment outcome to antiangiogenic therapy by means of both progression-free and overall survival (PFS and OS).The superpc predictor stratified patients in the discovery set into a low or high risk group for PFS (HR = 1.60; P = 0.017) and OS (HR = 2.14; P < 0.001) and was successfully validated for patients in the validation set (HR = 1.85, P = 0.030 for PFS; HR = 2.60, P = 0.001 for OS).Our radiomic-based superpc signature emerges as a putative imaging biomarker for the identification of patients who may derive the most benefit from antiangiogenic therapy, advances the knowledge in the noninvasive characterization of brain tumors, and stresses the role of radiomics as a novel tool for improving decision support in cancer treatment at low cost. Clin Cancer Res; 22(23); 5765-71. ©2016 AACR.
000128894 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000128894 588__ $$aDataset connected to CrossRef, PubMed,
000128894 7001_ $$0P:(DE-He78)abd768f879e71d08068d48fabb7e96cf$$aGötz, Michael$$b1$$udkfz
000128894 7001_ $$aMuschelli, John$$b2
000128894 7001_ $$aWick, Antje$$b3
000128894 7001_ $$aNeuberger, Ulf$$b4
000128894 7001_ $$aShinohara, Russell T$$b5
000128894 7001_ $$0P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b$$aSill, Martin$$b6$$udkfz
000128894 7001_ $$aNowosielski, Martha$$b7
000128894 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b8$$udkfz
000128894 7001_ $$0P:(DE-He78)77588f5b9413339755a66e739d316c7d$$aRadbruch, Alexander$$b9$$udkfz
000128894 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b10$$udkfz
000128894 7001_ $$aBendszus, Martin$$b11
000128894 7001_ $$0P:(DE-He78)33c74005e1ce56f7025c4f6be15321b3$$aMaier-Hein, Klaus$$b12$$udkfz
000128894 7001_ $$0P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93$$aBonekamp, David$$b13$$eLast author$$udkfz
000128894 773__ $$0PERI:(DE-600)2036787-9$$a10.1158/1078-0432.CCR-16-0702$$gVol. 22, no. 23, p. 5765 - 5771$$n23$$p5765 - 5771$$tClinical cancer research$$v22$$x1557-3265$$y2016
000128894 909CO $$ooai:inrepo02.dkfz.de:128894$$pVDB
000128894 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3da06896bf2a50a84d40c33c3b7a9b3e$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000128894 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)abd768f879e71d08068d48fabb7e96cf$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000128894 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000128894 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000128894 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)77588f5b9413339755a66e739d316c7d$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000128894 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000128894 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)33c74005e1ce56f7025c4f6be15321b3$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000128894 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000128894 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000128894 9141_ $$y2016
000128894 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN CANCER RES : 2015
000128894 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128894 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128894 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128894 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128894 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000128894 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128894 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128894 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000128894 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000128894 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCLIN CANCER RES : 2015
000128894 9201_ $$0I:(DE-He78)E012-20160331$$kE012$$lNeuroonkologische Bildgebung$$x0
000128894 9201_ $$0I:(DE-He78)E130-20160331$$kE130$$lComputer-assistierte medizinische Interventionen$$x1
000128894 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lRadiologie$$x2
000128894 9201_ $$0I:(DE-He78)G370-20160331$$kG370$$lKKE Neuroonkologie$$x3
000128894 9201_ $$0I:(DE-He78)E132-20160331$$kE132$$lMedizinische Bildverarbeitung$$x4
000128894 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x5
000128894 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x6
000128894 980__ $$ajournal
000128894 980__ $$aVDB
000128894 980__ $$aI:(DE-He78)E012-20160331
000128894 980__ $$aI:(DE-He78)E130-20160331
000128894 980__ $$aI:(DE-He78)E010-20160331
000128894 980__ $$aI:(DE-He78)G370-20160331
000128894 980__ $$aI:(DE-He78)E132-20160331
000128894 980__ $$aI:(DE-He78)C060-20160331
000128894 980__ $$aI:(DE-He78)L101-20160331
000128894 980__ $$aUNRESTRICTED